Astellas Pharma
4503.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥2.14T | ¥1.91T | ¥1.60T | ¥1.52T | ¥1.30T | ¥1.25T |
| Operating income | ¥382.6bn | ¥41.0bn | ¥25.5bn | ¥133.0bn | ¥155.7bn | ¥136.1bn |
| Net income (owners) | ¥291.5bn | ¥50.7bn | ¥17.0bn | ¥98.7bn | ¥124.1bn | ¥120.6bn |
| Total assets | ¥3.57T | ¥3.34T | ¥3.57T | ¥2.46T | ¥2.33T | ¥2.27T |
| Net assets / equity | ¥1.83T | ¥1.51T | ¥1.60T | ¥1.51T | ¥1.46T | ¥1.39T |
| Operating cash flow | ¥560.2bn | ¥194.5bn | ¥172.5bn | ¥327.8bn | ¥257.4bn | ¥306.8bn |
| EPS (basic) | ¥162.77 | ¥28.35 | ¥9.51 | ¥54.24 | ¥67.08 | ¥64.93 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 212 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 80 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 210 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 80 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 210 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2022-04-01 → 2023-03-31 | AnnualAmended | 210 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 210 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 210 figures · EDINET |
22 more reports are still being processed.